Revenue in Q2 2025 increased 38% to $15.56 billion driven by volume growth from Zepbound and Mounjaro. Increased the midpoint of our 2025 full-year revenue guidance by $1 .5 billion to be in the range of $60 billion to $62 billion ; reported EPS guidance raised to be in the range of $20.85 to